文献速递脊柱关节炎

晚发型脊柱关节炎表现为糖皮质激素抵抗的风湿性多肌痛:一种迄今未被充分认识、肿瘤坏死因子或白介素-17阻断可能具有治疗作用的疾病

Late-Onset Spondyloarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin -17 Blockade May Have a Therapeutic Role.
PubMed 文献 · Arthritis Rheumatol · 2025-12-08

该研究在利兹教学医院NHS信托基金会的银屑病关节炎或中轴型脊柱关节炎患者中,筛选2002至2024年间最初诊断为风湿性多肌痛(PMR)且回顾性符合2012年EULAR/美国风湿病学会分类标准或Bird等标准的31例患者。结果显示,这些表现为典型PMR肩/髋带疼痛的患者最终被归类为脊柱关节炎(SpA)谱系疾病,其特点是对糖皮质激素治疗失败或减量失败,并常通过MRI上SpA特异性骨炎模式识别。作者提出PMR-SpA重叠可能解释生物制剂在激素难治性PMR中的疗效。

要点

  • 31例最初诊断为PMR的患者最终归类为SpA谱系疾病,中位年龄62岁,女17例、男14例。
  • 25例接受MRI检查的患者中20例(80%)检出脊柱和/或骶髂关节骨髓水肿。
  • 21例初始糖皮质激素治疗临床缓解且CRP正常化,其中7例出现疾病复发或CRP升高。

核心结论

  • 晚发型SpA表现为PMR临床特征时,以对糖皮质激素治疗无反应或减量失败为特点,并常通过MRI上SpA特异性骨炎模式识别。
  • 作者提出PMR-SpA重叠可能解释生物制剂在激素难治性PMR中的疗效。

研究设计与样本

  • 在利兹教学医院NHS信托基金会观察的患者中,筛选2002至2024年间诊断为银屑病关节炎或中轴型SpA、且最初诊断为PMR的患者。
  • 仅纳入回顾性符合2012年EULAR/美国风湿病学会PMR分类标准或Bird等标准的患者。
  • 收集初始PMR诊断相关临床数据、影像学特征、随访和治疗数据,以及确立最终诊断的X线或MRI特征。

主要发现

  • 31例患者(中位年龄62岁[四分位距58-69];女17例、男14例)表现为典型PMR肩/髋带疼痛,随后被归类为SpA谱系疾病。
  • SpA诊断在12例患者于就诊后三个月内作出,19例患者在其余随访期间作出(中位3年[四分位距1-4])。
  • 27例接受检测的患者中4例HLA-B27阳性。
  • 25例接受MRI检查的患者中20例(80%)检出脊柱和/或骶髂关节骨髓水肿(骶髂关节:17例[68%];脊柱:15例[60%])。
  • 31例患者中21例在初始糖皮质激素治疗后临床缓解且CRP水平正常化,但这21例初始应答者中7例出现疾病复发或CRP水平升高。

关键数值与推荐

  • 31例患者中21例使用改善病情抗风湿药:8例接受传统合成改善病情抗风湿药,11例接受生物制剂(8例抗肿瘤坏死因子药物,3例白介素-17抑制剂),其余10例接受≤10 mg/天糖皮质激素治疗。
  • 25例接受MRI检查的患者中20例(80%)检出脊柱和/或骶髂关节骨髓水肿(骶髂关节:17例[68%];脊柱:15例[60%])。
  • 31例患者中21例在初始糖皮质激素治疗后临床缓解且CRP水平正常化,但这21例初始应答者中7例出现疾病复发或CRP水平升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Polymyalgia rheumatica (PMR) is an age-related inflammatory disease with shoulder/hip girdle involvement. Magnetic resonance imaging (MRI) reveals extracapsular/entheseal soft tissue involvement in both PMR and spondyloarthritis (SpA), with sacroiliac joint and perientheseal spinal bone marrow edema (BME) being characteristic of SpA. Therefore, some shared anatomic topography might be expected to result in similar clinical features. Herein, we describe the clinical and imaging features of SpA initially diagnosed as PMR. METHODS: Patients observed at Leeds Teaching Hospitals NHS Trust with a diagnosis of psoriatic arthritis (PsA) or axial SpA were screened to identify those initially diagnosed with PMR from 2002 to 2024. Only those patients who retrospectively fulfilled the 2012 EULAR/American College of Rheumatology classification criteria or the Bird et al criteria for PMR were included. Clinical data relevant to initial PMR diagnosis, imaging features, follow-up, and treatment data were collected, as well as radiographic or MRI features that established the final diagnosis. RESULTS: Thirty-one patients (median age 62 [interquartile range (IQR) 58-69] years; 17 women and 14 men) presenting with typical PMR shoulder/hip girdle pain were subsequently classified as having SpA spectrum disorders. The SpA diagnosis was made in 12 patients within three months of presentation and in 19 patients during the remaining follow-up period (median 3 [IQR 1-4] years). Four of 27 tested patients were HLA-B27 positive. BME on MRI was detected in the spine and/or sacroiliac joints in 20 of 25 patients (80%) who underwent imaging (sacroiliac joint: 17 patients [68%]; spine: 15 patients [60%]). Clinical resolution with C-reactive protein (CRP) level normalization occurred in 21 of 31 patients following initial glucocorticoid (GC) therapy, but 7 of these 21 initial responders experienced disease flares or elevations in CRP levels. Therapy-wise, disease-modifying antirheumatic drugs (DMARDs) were used in 21 of 31 patients: 8 received conventional synthetic DMARDs, and 11 received biologic agents (8 anti-tumor necrosis factor agents, 3 interleukin-17 inhibitors), whereas the remaining 10 patients were treated with ≤10 mg/day of GCs. CONCLUSION: Late-onset SpA with PMR clinical presentations is characterized by failure to respond to or taper GC therapy and is often identified by SpA-specific osteitis patterns on MRI. We propose that a PMR-SpA overlap may account for biologic therapy efficacy in steroid-refractory PMR.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Abacar K, De Marco G, Weddell J, et al. Late-Onset Spondyloarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin -17 Blockade May Have a Therapeutic Role. Arthritis Rheumatol. 2025. PMID: 40693392. doi:10.1002/art.43320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。